Psychedelic Research and Access in
Turkey
Blossom currently tracks 9 psychedelic clinical trials connected to Turkey. The country page also links to 2 stakeholders, giving the page ecosystem context beyond registered studies.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inTurkey.
- 1
Blossom tracks 9 psychedelic clinical trials connected to Turkey, with none currently marked active.
- 2
Visible trial compounds include Esketamine and Ketamine.
- 3
Visible trial topics include Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD) and Depressive Disorders.
- 4
The country page links to 2 stakeholders in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research and Access Snapshot
Blossom currently tracks 9 psychedelic clinical trials connected to Turkey.
- Active trials
- 0
- Total trials
- 9
- Stakeholders
- 2
- Events
- 0
None marked active
Linked to this country
Linked organisations
No linked events
Top Compounds
- Esketamine(5)
- Ketamine(4)
Top Study Topics
- Major Depressive Disorder (MDD)(4)
- Treatment-Resistant Depression (TRD)(3)
- Depressive Disorders(1)
- Peripartum(1)
Medical Access
Turkey maintains a restrictive national control regime for classical serotonergic and empathogenic psychedelics: most tryptamines, phenethylamines and classic psychedelic plants/ preparations are scheduled and not available outside authorised research or prosecution exceptions. Medical use of ketamine as an anaesthetic and analgesic is well established in Turkish clinical practice; esketamine (marketed as SPRAVATO in some markets) appears in Turkish product information sources but is not known to be broadly reimbursed by the public social security system...
Research Landscape
What the 9 registered trials connected to Turkey look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
What's live right now, and what stopped?
SourcedRegistry status of all 9 Turkey trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Regulatory Status
The linked medical access and reimbursement guide summarises Turkey as "Medical Only (Private)". Turkey maintains a restrictive national control regime for classical serotonergic and empathogenic psychedelics: most tryptamines, phenethylamines and classic psychedelic plants/ preparations are scheduled and not available outside authorised research or prosecution exceptions. Medical use of ketamine as an anaesthetic and analgesic is well established in Turkish clinical practice; esketamine (marketed as SPRAVATO in some markets) appears in Turkish product information sources but is not known to be broadly reimbursed by the public social security system (SGK) and is administered under specialist supervision.
Country Details
- Region
- Asia
- Last updated
- 15 Jul 2026
Country Report
Medical Only (Private)Medical Access
Turkey maintains a restrictive national control regime for classical serotonergic and empathogenic psychedelics: most tryptamines, phenethylamines and classic psychedelic plants/ preparations are scheduled and not available outside authorised research or prosecution exceptions. Medical use of...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Turkey.
Open scorecard →Psychedelic Stakeholders in Turkey
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Turkey.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Turkey.